

Dear colleagues,

Greetings from the Editor's Desk...!!

I bring to you yet another very interesting issue of our journal with many areas of discussion which need our attention, sensitivity and promotion. One such area is fertility preservation. Today, as we understand malignancies are on the rise, but early detection and management of such cases is increasing the life expectancy of many to a larger extent and in the last few decades as we have seen with increasing life expectancy and quality of life, more and more individuals are seeking fertility and it becomes mandatory for us clinicians to offer them fertility preservation before undertaking any of the treatment procedures like surgery, chemotherapy, radiotherapy or more.

It is not only for malignancy cases but also there are many other indications in men and women who would do well with fertility preservation as for example age-related fertility decline, premature ovarian insufficiency, certain medical conditions like endometriosis, lupus and Turner syndrome, gender identity and dysphoria are few to be named. There could be other social reasons for fertility preservation in women. What is important today is that we have the technology and techniques available to us for fertility preservation in any age-group from prepubescent to reproductive age-group. What is important here is to create awareness and make it as accessible as possible, of course expertise is required but not everyone is supposed to do early referral to the centers of excellence for the same, should be kept in mind. We can preserve sperm and testicular tissues for men and ovarian cortical tissue for women and embryos for couples. The other challenge being faced is that very few people are actually utilizing the cryopreserved materials, and this is another huge area which needs to be streamlined because of the cost involved and also other barriers. It would be really nice if we could expand the insurance coverage for fertility preservation for better utilization and also create mass education programs for patients and providers for a better utilization of the technology available.

I hope my little request to all of our readers will be well received and our countries should start formulating guidelines and recommendations for creating awareness and maximizing utilization of fertility preservation techniques. In the meantime, you can refer to the FIGO position statement on fertility preservation. (Link: <https://pubmed.ncbi.nlm.nih.gov/37807831/>)

Looking forward to many more interactions with all of you.



**Jaideep Malhotra**

Managing Director, Rainbow IVF, Agra, Uttar Pradesh, India

Chief of Editorial Board, SAFOMS Journal

Imm. Past Chair, FIGO Committee of Reproductive Medicine, Endocrinology, and Infertility

Past Member of FIGO Working Group on RDEH

Member of Accountability Group of PMNCH (WHO)

Past President, FOGSI, ISAR, ISPAT, ASPIRE, IMS